Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
Conditions
Interventions
Nemolizumab 30 mg
Placebo
Locations
100
United States
Galderma Investigational Site
Birmingham, Alabama, United States
Galderma Investigational Site
Birmingham, Alabama, United States
Galderma Investigational Site
Los Angeles, California, United States
Galderma Investigational Site
Sacramento, California, United States
Galderma Investigational Site
San Diego, California, United States
Galderma Investigational Site
San Diego, California, United States
Start Date
September 11, 2020
Primary Completion Date
November 11, 2022
Completion Date
February 21, 2023
Last Updated
July 10, 2024
NCT06342713
NCT06516952
NCT06779136
NCT04204616
NCT06427122
NCT06213831
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions